高渗性高血糖状态 中国就医指南

Hyperosmolar Hyperglycemic State (HHS) is a life-threatening acute metabolic complication of diabetes mellitus, predominantly occurring in patients with type 2 diabetes. It is characterized by extreme hyperglycemia (typically serum glucose >600 mg/dL), profound dehydration, elevated serum osmolality (>320 mOsm/kg), and absence of significant ketoacidosis (pH ≥7.30 and serum bicarbonate ≥18 mmol/L). Unlike diabetic ketoacidosis (DKA), HHS develops more insidiously—often over days to weeks—and reflects a severe deficit in effective circulating volume coupled with relative insulin sufficiency to suppress lipolysis but insufficient to prevent hyperglycemia. Pathogenesis centers on a combination of relative insulin deficiency, marked counterregulatory hormone excess (e.g., cortisol, catecholamines, glucagon), and impaired renal glucose clearance, frequently triggered by precipitating events such as infection (e.g., pneumonia, urinary tract infection), myocardial infarction, stroke, nonadherence to antihyperglycemic therapy, or use of diabetogenic medications (e.g., corticosteroids, thiazides, atypical antipsychotics). Dehydration worsens due to osmotic diuresis, leading to hypovolemic shock, altered mental status (ranging from confusion to coma), and multiorgan dysfunction—including acute kidney injury, rhabdomyolysis, and thromboembolic events. Epidemiologically, HHS carries higher mortality (10–20%) than DKA, especially among older adults (>65 years), with incidence estimated at 1–2 cases per 1,000 person-years among individuals with type 2 diabetes. Risk factors include advanced age, preexisting renal impairment, cognitive decline, limited access to healthcare, socioeconomic disadvantage, and comorbid conditions such as heart failure or dementia. Notably, up to one-third of HHS cases occur in previously undiagnosed diabetes. Quality of life impact is substantial: survivors often experience prolonged functional decline, increased dependency, cognitive deficits post-encephalopathy, recurrent hospitalizations, and heightened caregiver burden. Psychological sequelae—including anxiety, depression, and diabetes-related distress—are common, particularly when HHS results from treatment nonadherence or health literacy gaps. Early recognition hinges on vigilance for subtle symptoms: polyuria, profound thirst, dry mucous membranes, decreased skin turgor, lethargy, visual disturbances, and progressive neurologic changes. Delayed presentation significantly worsens prognosis; thus, patient education, community screening, and timely primary care referral are critical preventive strategies. In China, rising prevalence of type 2 diabetes—especially in aging urban and rural populations—has intensified HHS surveillance and standardized endocrine protocols across tertiary hospitals.

# 高渗性高血糖状态（HHS）治疗方案与费用明细（内分泌科）

一、非手术/保守治疗（首选方案）

适用于意识清醒、无休克、血浆渗透压＜350 mOsm/kg、无严重器官衰竭者。

• •基础治疗：静脉补液（0.45%氯化钠+胰岛素持续泵入）、电解质监测与纠正、病因筛查（感染/心梗/药物）
• •费用区间：

- 检查检验费（血糖/电解质/血气/渗透压/肝肾功/感染指标等）：¥1,200–¥2,600 - 药品费（胰岛素、氯化钾、抗生素等）：¥1,800–¥4,200

二、重症监护支持治疗（中重度HHS）

适用于GCS＜13分、收缩压＜90 mmHg、渗透压≥350 mOsm/kg或合并急性肾损伤者。

• •方案：ICU监护、中心静脉置管、连续性肾脏替代治疗（CRRT）必要时启用
• •费用区间：

- CRRT单次治疗费：¥2,200–¥3,600（按疗程计，通常3–5次） - 术前检查（含床旁超声、凝血功能、心电监护）：¥1,500–¥2,800

三、特殊复杂/并发症治疗

• •合并脓毒症：升级抗生素+血培养+降钙素原动态监测 → 增加费用¥3,000–¥6,500
• •急性脑水肿（罕见但危重）：甘露醇+高渗盐水+神经科会诊 → 增加费用¥2,000–¥4,800
• •多器官功能障碍（MODS）：多学科协作管理 → 总费用上浮30%–50%

方案快速选择指南

• •预算有限/轻症患者：选择普通病房保守治疗（总费用约¥12,000–¥22,000）
• •中重度/老年/合并感染：推荐ICU支持治疗（总费用约¥35,000–¥65,000）
• •反复发作/依从性差者：出院后强化糖尿病教育+胰岛素泵起始管理（门诊随访年均¥4,000–¥8,000）